Abstract

Compounded Pimobendan for Canine Chronic Degenerative Mitral Valve Disease and Pulmonary Hypertension

Author(s): Helms Scott R, Fox Samantha, Mixon William, Vail Jane

Issue: Jan/Feb 2012 - Volume 16, Number 1

Page(s): 34-41

Download in electronic PDF format for $75
  • Compounded Pimobendan for Canine Chronic Degenerative Mitral Valve Disease and Pulmonary Hypertension Page 1
  • Compounded Pimobendan for Canine Chronic Degenerative Mitral Valve Disease and Pulmonary Hypertension Page 2
  • Compounded Pimobendan for Canine Chronic Degenerative Mitral Valve Disease and Pulmonary Hypertension Page 3
  • Compounded Pimobendan for Canine Chronic Degenerative Mitral Valve Disease and Pulmonary Hypertension Page 4
  • Compounded Pimobendan for Canine Chronic Degenerative Mitral Valve Disease and Pulmonary Hypertension Page 5
  • Compounded Pimobendan for Canine Chronic Degenerative Mitral Valve Disease and Pulmonary Hypertension Page 6
  • Compounded Pimobendan for Canine Chronic Degenerative Mitral Valve Disease and Pulmonary Hypertension Page 7
  • Compounded Pimobendan for Canine Chronic Degenerative Mitral Valve Disease and Pulmonary Hypertension Page 8

Abstract

Pimobendan (Vetmedin) is an effective treatment for canine chronic degenerative mitral valve disease and dilated cardiomyopathy. In an off-label use, it may also be of benefit for the treatment of pulmonary hypertension in dogs. In this report, we describe the effects of a palatable customized oral form of pimobendan used with both compounded and commercially manufactured conventional drug therapy to treat degenerative mitral valve disease and pulmonary hypertension in two small dogs. For those patients, who resisted many types of oral medication, the standard manufactured dose of pimobendan was inappropriate. Formulations of the preparations used to treat the patients described in this report are provided for easy reference. It should be noted that at the time of this writing, Boehringer Ingelheim GmbH (Ingelheim am Rhein, Germany), the manufacturer of pimobendan, has expressed concern about the stability of that agent in aqueous compounded form. To our knowledge, no current data confirming the stability or bioequivalence of compounded pimobendan exist.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 2012
Pg. 34-41
May/Jun 2003
Pg. 188-191
Author(s): Davidson Gigi S
Jul/Aug 2003
Pg. 288-291
Author(s): Glasnapp Andrew
Jan/Feb 2013
Pg. 24-27
Author(s): Wung Deanna
Nov/Dec 2006
Pg. 421-424
Author(s): Vail Jane
Jul/Aug 1997
Pg. 242-243
Nov/Dec 2006
Pg. 405-408
Author(s): Davidson Gigi S
Jan/Feb 2012
Pg. 12-16
Author(s): McElhiney Linda F
Jan/Feb 2011
Pg. 27-31
Sep/Oct 2010
Pg. 382-394
Mar/Apr 2011
Pg. 114-116
May/Jun 2002
Pg. 210-215
Author(s): Davidson Gigi S
Sep/Oct 2008
Pg. 384-390
Author(s): Davidson Gigi S
Sep/Oct 2012
Pg. 364-368
Mar/Apr 2011
Pg. 124-128
Nov/Dec 2010
Pg. 488-491
Jan/Feb 2010
Pg. 40-45
Jul/Aug 2022
Pg. 293-296
May/Jun 2004
Pg. 181-185
Mar/Apr 2001
Pg. 92-94
Author(s): Davidson Michael G